Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Proven human resources and organizational strategist brings more than two decades of leadership across the pharmaceutical industryAppointment supports Helus Pharma’s continued maturation as the...
-
Statistically significant (p<0.0001) and clinically meaningful improvement in Hamilton Anxiety Rating Scale (“HAM-A”) of ~10 points on top of Standard of Care (“SoC”) at 6 weeksDurable effects...
-
In this role, Dr. Lewis-Hall will guide clinical development strategy, regulatory engagement, and translational rigor across Helus’ novel serotonergic agonist (“NSA”) portfolio This news release...
-
Randomized, placebo-controlled Phase 2a study of SPL026 met its primary endpoint demonstrating a clinically significant reduction in depressive symptoms as measured by MADRS score (mean difference:...
-
HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights
- Cash position of US$195 million as of December 31, 2025, before adjustment for post quarter events -- Topline data readout from the Phase 2 study evaluating HLP004 in generalized anxiety disorder...
-
Ex-presidente da empresa farmacêutica especializada da Shire PLC ("Shire"), com mais de 30 anos de experiência em neurociência, doenças raras e produtos farmacêuticos especializados, incluindo cargos...
-
Bekas Presiden perniagaan Farmaseutikal Khusus Shire PLC (“Shire”), dengan lebih 30 tahun pengalaman merentasi bidang neurosains, penyakit jarang jumpa dan farmaseutikal khusus, termasuk memegang...
-
Shire PLC(“Shire”) 전문의약품 사업부 전 사장으로, 신경과학·희귀질환·전문의약품 분야에서 30년 이상 경력 보유, Astra-Merck 및 AstraZeneca PLC에서 고위 리더십 역할 수행중추신경계(CNS) 프로그램 전반에 걸친 후기 임상 개발, 글로벌 상업화 및 자본 조달 분야에서 입증된 리더이번 분기 HLP004의 2상 데이터 발표...
-
• נשיא לשעבר של עסקי התרופות הייעודיות של Shire PLC ("Shire"), עם יותר מ-30 שנות ניסיון בתחומי מדעי המוח, מחלות נדירות ותרופות ייעודיות, כולל תפקידי ניהול בכירים ב-Astra-Merck ו-AstraZeneca PLC •...
-
曾出任 Shire PLC（簡稱「Shire」）專科製藥業務總裁，在神經科學、罕見疾病及專科製藥範疇擁有 30 多年豐富經驗，曾於 Astra-Merck 及 AstraZeneca PLC 擔當高層領導職務在中樞神經系統（簡稱「CNS」）項目的後期臨床開發、全球商業化及資金募集方面具備有目共睹的領導才能此任命正值 Helus Pharma...